Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Actos · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Aleglitazar | EXPERIMENTAL | - |
| Actos | ACTIVE_COMPARATOR | - |
| Aleglitazar 1 | EXPERIMENTAL | - |
| Aleglitazar 2 | EXPERIMENTAL | - |
| Aleglitazar 3 | EXPERIMENTAL | - |
| Aleglitazar 4 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Actos | DRUG | 45mg po daily |
| aleglitazar | DRUG | 0.6mg po daily |
| Placebo | DRUG | po daily |
Inclusion Criteria: * adult patients, 18-75 years of age; * type 2 diabetes for \>=1 month; * drug naive, or receiving stable oral antihyperglycemic medication; * HbA1c 6.5-10.0% at screening. Exclusion Criteria: * type 1 diabetes; * current or previous treatment with insulin; * history of renal ...
Actos is used for the treatment of Diabetes Mellitus Type 2. It is a small molecule being developed by Roche Holding AG (RHHBY). In clinical trials, Actos has been studied as a comparator in patients with type 2 diabetes, including those with NYHA Class II heart failure.
Actos is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is a small molecule in the metabolic therapeutic area, specifically targeting Diabetes Mellitus Type 2. Roche has conducted Phase 2 clinical trials involving Actos as a comparator.
Actos is in Phase 2 clinical development. It has been studied in three completed Phase 2 trials, all of which were randomized, double-blind, and placebo-controlled. These trials enrolled a total of 522 patients with Diabetes Mellitus Type 2.
Actos has been involved in three completed Phase 2 trials: NCT00388518, a study of aleglitazar in type 2 diabetes with 332 patients; NCT00461006, comparing effects on renal function with 176 patients; and NCT00461058, a comparative study in patients with NYHA Class II heart failure with 14 patients.
No, Actos is not the same as aleglitazar. In the clinical trials, Actos was used as a comparator against aleglitazar, which was the investigational drug being studied. Actos is a separate drug developed by Roche Holding AG for Diabetes Mellitus Type 2.